| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Thomas Adams PhD last filed a Form 4 in June 2021, as Director at CRDF. Thomas Adams PhD's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 18,875 shares of CRDF. Net of sales, the CRDF filings show accumulation of 13,986 shares.
Thomas Adams PhD has 15 Form 4 filings on record from March 2015 to June 2021, across 2 companies: Former Director at Cardiff Oncology (CRDF), 2015–2021; Director at Hepion Pharmaceuticals (HEPA), 2019–2021.
The 21 reported transactions were 11 option or other derivative awards, 7 other transactions, 2 option exercises and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $20K and no sales.
The only open-market purchase was 13,986 shares of CRDF at an average $1.43 on May 14, 2020, about $20K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 14, 2020 | CRDF Cardiff Oncology, Inc. | Director | Buy | 13,986 | $1.43 | $19,999.98 | +286.1% |